Back to Mentors

Dr. Franz Humer

Major Career Roles:

  • Chair of Roche Holding AG
  • Chair of Diageo
  • Chair of Neogene Therapeutics
  • Chair of HMNC Holding Brain Health GmbH
  • Independent Director Allogene Therapeutics
  • Member of the Board of Directors of Emil Frey Holdings (largest European car dealership


Other Career Highlights:

  • COO of Glaxo PLC
  • Board Member of Allianz SE
  • Vice Chairman of Wisekey Intl. holding LTD
  • Senior Independent NED Arix Bioscience PLC
  • Member of the Board of Directors, Citigroup Inc. New York
  • Independent Director Kite Pharma INC
  • Director Chugai Pharmaceutical Company LTD
  • Independent Director Zurich Insurance Group AG
  • Chair of INSEAD
  • Chair of the Board of Directors of the International Centre for Missing and Exploited Children
  • Advisor to Breakthrough Properties (USA)

Dr. Franz Humer has over 30 years of international experience serving as Chair across FTSE 100, SMI, STOXX Europe 50 companies giving him a vast wealth of multi-industry knowledge of pharmaceutical and biotech, and private equity companies.


Dr Franz Humer was previously Chair of Roche Holding AG, Chair of Diageo and Neogene Therapeutics. He is currently Chair of HMNC Brain Health and Chair of the Board of Directors of the International Centre for Missing & Exploited Children and Chair of the Humer Foundation.


Professional experience from positions in the pharmaceuticals industry at, among others, Schering Plough Corp. and Glaxo where he was Managing Director of Glaxo Pharmaceuticals UK and a member of the Board of Glaxo Holdings plc.  In 1995, he joined Hoffmann-La Roche as a member of its Board and the Head of its Pharmaceutical Division, progressing to become Chair and CEO in 2001, and between 2008 and 2014 the Chair of Roche Holding Limited.


Franz was an Independent Director with Citigroup Inc., Chugai Pharmaceuticals Ltd (Japan), Arix Bioscience plc and Kite Pharma (biotech company in Los Angeles).


In addition to Franz’s chair roles he is currently a Board Director of Allogene Therapeutics and Emil Frey Holdings and an Advisor to Temasek Holdings, Letterone Healthcare, Target PharmaSolutions and Breakthrough Properties in addition to a number of start-up companies.